Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
- Authors:
- Octavia O. Căpățînă
- Ioana V. Micluția
- Mihaela Fadgyas-Stănculete
-
Affiliations: Department of Neurosciences, ‘Iuliu Hațieganu’ University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania - Published online on: January 25, 2021 https://doi.org/10.3892/etm.2021.9707
- Article Number: 276
-
Copyright: © Căpățînă et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Kirkpatrick B, Fenton WS, Carpenter WT Jr and Marder SR: The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 32:214–219. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, et al: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet. 394:939–951. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Buchanan RW: Persistent negative symptoms in schizophrenia: An overview. Schizophr Bull. 33:1013–1022. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Căpățînă O and Micluția I: Internalized stigma as a predictor of quality of life in schizophrenia. J Evid Based Psychother. 19:35–53. 2018. | |
|
Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG and Kapur S: Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophr Res. 137:147–150. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Salvan H, Stanculete M and Macrea R: Frequency of sexual dysfunction in patients with schizophrenia. Eur Psychiatry. 22 (Suppl)(S138)2007. | |
|
Bobes J, Arango C, Garcia-Garcia M and Rejas J: CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study. J Clin Psychiatry. 71:280–286. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Tsapakis EM, Dimopoulou T and Tarazi FI: Clinical management of negative symptoms of schizophrenia: An update. Pharmacol Ther. 153:135–147. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Murphy BP, Chung YC, Park TW and McGorry PD: Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophr Res. 88:5–25. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Buchanan RW, Breier A, Kirkpatrick B, Ball P and Carpenter WT Jr: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 155:751–760. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Puia IC, Stanculete MF, Hopulele-Petri A, Muresan D and Puia A: Patients' perception of weight-related stigma in a Romanian sample. J Evid Based Psychother. 17:147–157. 2017. | |
|
Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S and Leucht S: Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. (CD006633)2010.PubMed/NCBI View Article : Google Scholar | |
|
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, et al: CATIE Investigators: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 163:600–610. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Liang Y and Yu X: Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: A subanalysis of the ESCAPE study. Neuropsychiatr Dis Treat. 13:1703–1712. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A and Leucht S: Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: A systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 268:625–639. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E and Durgam S: Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 29:127–136. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Pilla Reddy V, Kozielska M, Suleiman AA, Johnson M, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M and Proost JH: Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score. Schizophr Res. 146:153–161. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Shafti SS and Gilanipoor A: A comparative study between olanzapine and risperidone in management of schizophrenia. Schizophr Res Treat. 2014(307202)2014.PubMed/NCBI View Article : Google Scholar | |
|
Balaraman R and Gandhi H: Asenapine, a new sublingual atypical antipsychotic. J Pharmacol Pharmacother. 1:60–61. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Potkin SG, Cohen M and Panagides J: Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial. J Clin Psychiatry. 68:1492–1500. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Potkin SG, Phiri P, Szegedi A, Zhao J, Alphs L and Cazorla P: Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: A pooled analysis. Schizophr Res. 150:442–449. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M and Németh G: The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 58:1–9. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y, Patel M, Barabássy Á, Szatmári B and Németh G: Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res. 204:282–288. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Lasser RA, Dirks B, Nasrallah H, Kirsch C, Joseph Gao, Pucci ML, Knesevich MA and Lindenmayer JP: Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: Open label and randomized controlled trial. Soc Psychiatry Psychiatr Epidemiol. 38:2140–2149. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Lindenmayer JP, Nasrallah H, Pucci M, James S and Citrome L: A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: Challenges and therapeutic opportunities. Schizophr Res. 147:241–252. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Goff DC: D-cycloserine: An evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull. 38:936–941. 2012.PubMed/NCBI View Article : Google Scholar | |
|
de Bartolomeis A, Sarappa C, Magara S and Iasevoli F: Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia. Eur J Pharmacol. 682:1–11. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, et al: Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 71:637–646. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Singer P, Dubroqua S and Yee BK: Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy? Curr Pharm Des. 21:3771–3787. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Mazinani R, Nejati S and Khodaei M: Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial. Psychiatry Res. 247:291–295. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M and Akhondzadeh S: Memantine add-on to risperidone treatment of negative symptoms in patients with stable schizophrenia. J Clin Psychopharmacol. 33:336–342. 2013.PubMed/NCBI View Article : Google Scholar | |
|
de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, et al: Improvement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 70:1416–1423. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Kishi T, Matsuda Y and Iwata N: Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: A meta-analysis. Psychopharmacology (Berl). 234:2113–2125. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Ritsner MS, Bawakny H and Kreinin A: Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: An 8-week, double-blind, randomized add-on two-center trial. Psychiatry Clin Neurosci. 68:432–440. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Momtazmanesh S, Zare-Shahabadi A and Rezaei N: Cytokine alterations in schizophrenia: An updated review. Front Psychiatry. 10(892)2019.PubMed/NCBI View Article : Google Scholar | |
|
Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS and Burger H: Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 71:520–527. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Cho M, Lee TY, Kwak YB, Yoon YB, Kim M and Kwon JS: Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. Aust N Z J Psychiatry. 53:742–759. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM and Sommer IEC: An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: A meta-analysis. Psychol Med. 49:2307–2319. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Schmidt L, Phelps E, Friedel J and Shokraneh F: Acetylsalicylic acid (aspirin) for schizophrenia. Cochrane Database Syst Rev. 8(CD012116)2019.PubMed/NCBI View Article : Google Scholar | |
|
Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, Visco AC, Metzler E, Zhang Y and Francis MM: Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. 199:395–402. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, et al: N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 36:185–192. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Sepehrmanesh Z and Heidary M, Akasheh N, Akbari H and Heidary M: Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 82:289–296. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, et al: N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 64:361–368. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Zhang L, Zheng H, Wu R, Zhu F, Kosten TR, Zhang XY and Zhao J: Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Prog Neuropsychopharmacol Biol Psychiatry. 85:69–76. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Oya K, Kishi T and Iwata N: Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol. 29:483–491. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Bennett AC and Vila TM: The role of ondansetron in the treatment of schizophrenia. Ann Pharmacother. 44:1301–1306. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Samadi R, Soluti S, Daneshmand R, Assari S and Manteghi AA: Efficacy of risperidone augmentation with ondansetron in the treatment of negative and depressive symptoms in schizophrenia: A randomized clinical trial. Iran J Med Sci. 42:14–23. 2017.PubMed/NCBI | |
|
Kishi T, Mukai T, Matsuda Y and Iwata N: Selective serotonin 3 receptor antagonist treatment for schizophrenia: Meta-analysis and systematic review. Neuromolecular Med. 16:61–69. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, Reilly J, Schaffhauser JY, Rabinowitz J, Weiser M and Luthringer R: Efficacy and safety of MIN-101: A 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 174:1195–1202. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Singh SP, Singh V, Kar N and Chan K: Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. Br J Psychiatry. 197:174–179. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Rummel C, Kissling W and Leucht S: Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev: CD005581, 2006 doi: 10.1002/14651858 D005581. | |
|
Möller HJ: Management of the negative symptoms of schizophrenia: New treatment options. CNS Drugs. 17:793–823. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Caforio G, Di Giorgio A, Rampino A, Rizzo M, Romano R, Taurisano P, Fazio L, De Simeis G, Ursini G, Blasi G, et al: Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia. J Clin Psychopharmacol. 33:810–812. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, Lee JE, Suh S, Yook KH and Lee SH: Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 35:208–211. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Tsai CH, Chen TT and Huang WL: Combination of escitalopram and aripiprazole causes significant improvement of negative symptoms of simple schizophrenia. Psychiatry Clin Neurosci. 68:582–583. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Hinkelmann K, Yassouridis A, Kellner M, Jahn H, Wiedemann K and Raedler TJ: No effects of antidepressants on negative symptoms in schizophrenia. J Clin Psychopharmacol. 33:686–690. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, et al: Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. J Clin Psychiatry. 75:608–615. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Nikbakhat MR, Arabzadeh S, Zeinoddini A, Khalili Z, Rezaei F, Mohammadinejad P, Ghaleiha A and Akhondzadeh S: Duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Pharmacopsychiatry. 49:162–169. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Ding N, Li Z and Liu Z: Escitalopram augmentation improves negative symptoms of treatment resistant schizophrenia patients-A randomized controlled trial. Neurosci Lett. 681:68–72. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball MP and Buchanan RW: The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol. 32:69–74. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Choi KH, Wykes T and Kurtz MM: Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: Meta-analytical investigation of efficacy. Br J Psychiatry. 203:172–178. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Singh J, Kour K and Jayaram MB: Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev. 1(CD007967)2012.PubMed/NCBI View Article : Google Scholar | |
|
Hayes E, Gavrilidis E and Kulkarni J: The role of estrogen and other hormones in the pathophysiology and treatment of schizophrenia. Schizophr Res Treat. 2012(540273)2012.PubMed/NCBI View Article : Google Scholar | |
|
Kulkarni J, de Castella A, Headey B, Marston N, Sinclair K, Lee S, Gurvich C, Fitzgerald PB and Burger H: Estrogens and men with schizophrenia: Is there a case for adjunctive therapy? Schizophr Res. 125:278–283. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Begemann MJ, Dekker CF, van Lunenburg M and Sommer IE: Estrogen augmentation in schizophrenia: A quantitative review of current evidence. Schizophr Res. 141:179–184. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A and Akhondzadeh S: Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: An 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs. 27:57–65. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Oya K, Matsuda Y, Matsunaga S, Kishi T and Iwata N: Efficacy and safety of oxytocin augmentation therapy for schizophrenia: An updated systematic review and meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci. 266:439–450. 2016.PubMed/NCBI View Article : Google Scholar |
